RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81

Benzinga Newsdesk www.benzinga.com Negative 95.1%

Neg 95.1% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.